Jump to content
Content on WikiMesothelioma is reviewed by three named attorneys at Danziger & De Llano LLP prior to publication. See our editorial standards.

Surgery for Unresectable Pleural Mesothelioma

From WikiMesothelioma — Mesothelioma Knowledge Base
Surgery for Unresectable Pleural Mesothelioma
Palliative surgical options when curative resection is not possible
Topic Detail
Patient population Unresectable or borderline-resectable disease
Surgical intent Palliative — symptom control, not cure
Main procedures VATS partial pleurectomy, indwelling pleural catheter, partial pleurectomy/decortication
Active trial NCT07126509 (University of Chicago)
Trial endpoint LCSS-Meso symptom burden at 3 months
Shared cause Asbestos exposure

Executive Summary

Being told that mesothelioma is "inoperable" means curative surgery is off the table — it does not mean surgery has nothing to offer. For patients with pleural mesothelioma who are not candidates for aggressive, curative-intent resection, a separate set of palliative surgical procedures exists to control symptoms, drain fluid, and improve quality of life.[1][2] This page covers that distinct patient population — the people who have failed the eligibility screen for curative surgery described in Mesothelioma Surgery — and the surgical options that remain for them.

Patients are judged unresectable for a combination of reasons: non-epithelioid (sarcomatoid or biphasic) histology, disease that has spread across the diaphragm or to lymph nodes, metastatic disease, or insufficient heart-and-lung reserve to survive a major operation.[2][3] Importantly, the line between "resectable" and "unresectable" has itself shifted. The MARS 2 trial reported in 2024 that extended pleurectomy/decortication plus chemotherapy did not improve survival compared with chemotherapy alone, even in patients who were operable — reinforcing that, for those ineligible for curative resection, the goal of any surgery shifts entirely to symptom relief.[4]

For this population, standard first-line treatment is systemic therapy: the combination of nivolumab plus ipilimumab extended median overall survival to 18.1 months versus 14.1 months with chemotherapy in the CheckMate 743 trial of unresectable disease.[5] Around that systemic backbone, palliative surgery manages the mechanical problems the tumor creates — recurrent pleural effusions, breathlessness, and a lung trapped by tumor rind. Options range from talc pleurodesis and indwelling pleural catheters to video-assisted thoracoscopic (VATS) partial pleurectomy and, increasingly, limited partial pleurectomy with decortication now being studied formally in a University of Chicago clinical trial (NCT07126509).[6][7] An accurate diagnosis and surgical assessment also document the disease and its prognosis, which support a patient's right to pursue compensation for asbestos exposure.

At-a-Glance

Surgery for unresectable pleural mesothelioma at a glance:

  • Inoperable is not untreatable — patients who cannot have curative surgery still have palliative surgical options to control symptoms and fluid.[1][2]
  • Unresectability has defined criteria — sarcomatoid or biphasic histology, transdiaphragmatic or nodal spread, metastatic disease, and poor cardiopulmonary reserve are the main determinants.[2][3]
  • MARS 2 reframed surgical value — extended pleurectomy/decortication plus chemotherapy did not improve survival over chemotherapy alone even in operable patients.[4]
  • Systemic therapy is the backbone — nivolumab plus ipilimumab extended median survival to 18.1 months versus 14.1 months with chemotherapy in unresectable disease.[5]
  • VATS partial pleurectomy controls effusion — the MesoVATS randomized trial compared it against talc pleurodesis for symptom control.[6]
  • Indwelling pleural catheters reduce hospital time — the AMPLE trial found IPCs cut hospitalization days versus talc pleurodesis.[8][9]
  • Trapped lung is the key challenge — when tumor encases the lung it cannot re-expand, so pleurodesis alone fails and a catheter or decortication is needed.[10][11]
  • Epithelioid histology predicts success — the earliest palliative-debulking series found epithelioid patients had better symptom control and survival.[11]
  • An active trial is studying this population — NCT07126509 at the University of Chicago is testing limited partial pleurectomy in unresectable and borderline epithelioid patients.[7]

Key Facts

Palliative option What it does Evidence base
Talc pleurodesis Seals the pleural space to stop fluid re-accumulating ERS/EACTS effusion statement[10]
Indwelling pleural catheter (IPC) Drains fluid at home; preferred when the lung is trapped TIME2 and AMPLE randomized trials[9][8]
VATS partial pleurectomy Minimally invasive removal of tumor-bearing pleura for symptom control MesoVATS randomized trial[6]
Palliative surgical debulking Decortication to relieve a trapped lung and breathlessness Martin-Ucar 2001 series (n=51)[11]
Limited partial pleurectomy (trial) Palliative-intent debulking under formal study NCT07126509, University of Chicago[7]

Who Is Considered Unresectable for Curative Mesothelioma Surgery?

A patient is judged "unresectable" — not a candidate for curative-intent surgery — when the disease or the patient's overall condition makes a major operation unlikely to extend life. The determinants are well described in the surgical literature and in current expert consensus.[2][3]

The strongest single factor is tumor histology. Sarcomatoid and biphasic mesothelioma behave far more aggressively than epithelioid disease, and patients with non-epithelioid tumors generally do not benefit from aggressive resection. Beyond cell type, anatomic spread removes the surgical option: disease that crosses the diaphragm into the abdomen, involves mediastinal (N2) lymph nodes, has become bilateral, or has metastasized cannot be cleared by an operation confined to one pleural cavity.[2] Finally, physiologic reserve matters — a patient must have enough heart and lung function to survive and recover from surgery, and many mesothelioma patients, who are often older and have a history of occupational lung exposure, do not.[3]

This page is the counterpart to the eligibility discussion in Mesothelioma Surgery. Where that page describes who qualifies for curative surgery such as Pleurectomy Decortication or Extrapleural Pneumonectomy, this page is for the larger group of patients who do not — and explains what can still be done surgically to help them feel better.

What Surgical Options Remain When Curative Surgery Is Not Possible?

When cure is not the goal, surgery shifts to palliation — relieving the symptoms the tumor causes rather than attempting to remove all of it. In pleural mesothelioma, the dominant symptom is breathlessness, driven by recurrent pleural effusion (fluid around the lung) and by the lung becoming encased in a rind of tumor. The palliative surgical spectrum is built to address exactly these problems.[1][10]

The least invasive options manage fluid. Talc pleurodesis instills talc into the pleural space to make the two pleural layers stick together, preventing fluid from re-accumulating.[10] An indwelling pleural catheter (IPC) is a thin, tunneled tube the patient can drain at home, avoiding repeated hospital visits.[9][8] More involved options are surgical: VATS partial pleurectomy uses keyhole (video-assisted thoracoscopic) access to strip away tumor-laden pleura and free the lung, and partial pleurectomy with decortication goes further to peel the tumor rind off a trapped lung.[6][11] The companion patient guide, Palliative Pleurectomy for Inoperable Mesothelioma, walks through these options in plain language for patients and families.

What Is Palliative Surgical Debulking?

Palliative surgical debulking removes as much tumor as is safely possible to relieve symptoms, without the goal — or the morbidity — of a full curative resection. The earliest formal evidence comes from a series of 51 consecutive patients reported by Martin-Ucar and colleagues in 2001, in which VATS pleurectomy or open decortication was used to control symptoms; epithelioid histology predicted both longer survival and more successful symptom control.[11] That finding — that the same epithelioid patients who do best with other treatments also do best with palliative surgery — still shapes patient selection today.

The most rigorous comparison is the MesoVATS randomized controlled trial, which tested VATS partial pleurectomy against talc pleurodesis in patients with malignant pleural effusion from mesothelioma. VATS partial pleurectomy did not deliver a survival advantage, but the trial established it as a defined option within the symptom-control toolkit and clarified which patients are most likely to benefit.[6] The lesson across both studies is consistent: palliative debulking is about quality of life and symptom relief, measured honestly, rather than a smaller version of curative surgery.

How Are Pleural Effusions and Trapped Lung Managed?

Recurrent pleural effusion is the most common reason a mesothelioma patient becomes breathless, and managing it is the first job of palliative care. Two randomized trials define the modern choices. The TIME2 trial compared an indwelling pleural catheter against chest tube and talc pleurodesis for relieving breathlessness and found both effective, with the catheter avoiding an inpatient stay.[9] The AMPLE trial then showed that indwelling pleural catheters reduced total hospitalization days compared with talc pleurodesis — an outcome that matters greatly to patients with limited time.[8]

The harder problem is trapped lung. When tumor forms a thick rind around the lung, the lung physically cannot re-expand to fill the chest after fluid is drained. In that situation talc pleurodesis fails — there is no lung surface to stick to the chest wall — and the patient needs either an indwelling catheter to manage symptoms or a decortication to peel the rind away and let the lung breathe again.[10][11] Recognizing trapped lung before attempting pleurodesis is one of the most important judgments in managing unresectable disease, and it is precisely the scenario in which surgical debulking earns its place.[10]

What Does the MARS 2 Trial Mean for Surgical Candidacy?

The MARS 2 trial, reported in 2024, is essential context for understanding surgery in this disease. It randomized patients with resectable pleural mesothelioma to extended pleurectomy/decortication plus chemotherapy versus chemotherapy alone — and found that adding surgery did not improve survival, with signals of greater harm in the surgical arm.[4] Crucially, MARS 2 studied patients who were operable.

The implication for unresectable patients is not that surgery is futile, but that the rationale for surgery has narrowed. If aggressive curative-intent surgery does not extend life even in operable patients, then for patients who are not operable the surgical goal shifts entirely to symptom relief — a fundamentally different objective with a different risk-benefit calculation.[4][3] This is why current surgery for the unresectable population is framed as palliative from the outset, and why a trial like NCT07126509 measures symptom burden rather than survival as its primary endpoint.

How Do Systemic Therapy and Palliative Surgery Work Together?

For unresectable pleural mesothelioma, systemic therapy is the backbone of treatment, and palliative surgery is layered around it. The CheckMate 743 trial established first-line nivolumab plus ipilimumab for unresectable disease, extending median overall survival to 18.1 months versus 14.1 months with platinum-based chemotherapy.[5] Patient-reported outcomes from the same trial showed that immunotherapy maintained quality of life relative to chemotherapy, measured with the validated LCSS-Meso instrument.[12]

The timing between the two matters. In the University of Chicago trial protocol, patients must complete at least six weeks of systemic induction therapy before palliative surgery is considered, and they must not have progressed during that time — surgery is reserved for patients whose disease is controlled enough that debulking can help.[7] After surgery, systemic therapy resumes, and how quickly a patient can return to it is one of the trial's secondary endpoints.[7] The sequence reflects a core principle: palliative surgery supports, and does not replace, the systemic treatment that drives survival in this disease.[1][13]

What Is the University of Chicago Partial Pleurectomy Trial (NCT07126509)?

NCT07126509 is a pilot clinical trial — "A Pilot Study of Partial Pleurectomy in Borderline and Unresectable Pleural Mesothelioma" — run by the University of Chicago Medicine Comprehensive Cancer Center and led by Darren Bryan, MD. It is the first formal study to ask, in a structured way, whether limited partial pleurectomy with decortication improves symptoms in patients who are not candidates for curative surgery.[7]

The trial is recruiting, with a target enrollment of 30 patients and an estimated primary completion in December 2028. Eligibility is deliberately narrow: histologically confirmed epithelioid mesothelioma only; unilateral disease that is unresectable or borderline-resectable; completion of at least six weeks of systemic induction therapy without progression; and an ECOG performance status of 0 to 1. Patients with biphasic or sarcomatoid histology, metastatic disease, or progression on induction are excluded.[7] The primary endpoint is symptom burden measured by the LCSS-Meso Average Symptom Burden Index (ASBI) at three months, with quality of life, complication rate, time to resumption of systemic therapy, and overall survival as secondary endpoints.[7][14] Patients interested in trial participation should consult the registry listing and discuss eligibility with a mesothelioma specialist; see Clinical Trials Mesothelioma for the broader trial landscape.

Why Does the LCSS-Meso Symptom Score Matter?

Because palliative surgery aims at symptoms rather than survival, the way symptoms are measured is central to proving whether it works. The Lung Cancer Symptom Scale adapted for mesothelioma (LCSS-Meso) is the validated instrument for this purpose. It was validated in a study of 495 patients with unresectable pleural mesothelioma and captures pain, breathlessness, fatigue, appetite loss, and the disease's overall impact on daily activity.[14] The Average Symptom Burden Index (ASBI) summarizes these into a single score — a lower score means better symptom control.

The LCSS-Meso ASBI is not a niche research tool; it is the same instrument used to measure patient-reported outcomes in CheckMate 743, the trial that defined first-line immunotherapy for this population.[12] Its use as the primary endpoint of NCT07126509 means the trial is asking a patient-centered question — does the operation make people feel better — rather than only a survival question, which is the appropriate standard for a palliative intervention.[14][12]

Who Qualifies for Palliative Surgical Debulking?

Selection for palliative surgical debulking is careful, because the operation must help more than it harms in patients with limited reserve. The pattern that emerges across the evidence and the active trial is consistent. Epithelioid histology is the central requirement: the Martin-Ucar series found epithelioid patients had the best symptom control and survival, and NCT07126509 enrolls epithelioid patients exclusively.[11][7] Patients should also have completed systemic induction therapy without progression, demonstrating that their disease is controlled enough for surgery to add value, and they must have adequate performance status to tolerate the procedure.[7][2]

Just as important is the process. The Society of Thoracic Surgeons' 2026 expert consensus emphasizes that surgical decisions in mesothelioma should be made through multidisciplinary team (MDT) discussion, not by any single clinician — bringing together thoracic surgery, medical oncology, radiation oncology, and palliative care to weigh whether surgery fits a given patient's goals.[3] For the unresectable patient, that conversation is explicitly about quality of life, and the MDT is the safeguard that keeps palliative surgery aimed at the patient's benefit.

What Do Treatment Guidelines Recommend?

Major guidelines converge on a consistent picture for unresectable disease. The American Society of Clinical Oncology (ASCO) guideline recognizes VATS partial pleurectomy as an acceptable option for symptom control in symptomatic patients who are not candidates for curative surgery, and positions systemic therapy as the foundation of care.[1] The European ERS/ESTS/EACTS/ESTRO guideline similarly makes systemic therapy the standard for advanced and unresectable mesothelioma, with surgical procedures reserved for palliation of symptoms.[13]

The most recent statement, the Society of Thoracic Surgeons 2026 expert consensus, strongly favors pleurectomy/decortication over extrapleural pneumonectomy when surgery is appropriate at all, and reinforces that patients who are not eligible for curative surgery represent a distinct management category requiring multidisciplinary input.[3] For pleural effusion specifically, the ERS/EACTS statement on malignant pleural effusions guides the choice between pleurodesis and indwelling catheters and addresses the management of trapped lung.[10] Across all of them, the message for the inoperable patient is the same: treatment continues, and surgery still has a defined, symptom-focused role.

What Compensation Is Available for Inoperable Mesothelioma?

A diagnosis of unresectable mesothelioma does not reduce a patient's legal rights — it often makes timely action more important. Mesothelioma is caused almost exclusively by asbestos exposure, and patients who were exposed at work, in military service, or through a family member's contaminated clothing may be entitled to compensation regardless of whether their disease is operable.[3] An accurate diagnosis and surgical assessment help by documenting the specific disease and its prognosis, which inform the value of a claim.

Several recovery paths may apply at once. Asbestos Trust Funds established by bankrupt manufacturers, civil litigation against solvent defendants, and VA benefits for service-related exposure can often be pursued together. Because the more aggressive disease patterns common in unresectable cases can shorten the window for filing, and because every state sets a statute of limitations, families benefit from understanding their options early. For an overview of how compensation works across all stages of mesothelioma, see Mesothelioma Compensation.

Frequently Asked Questions

Can I have surgery if my mesothelioma is inoperable? Often, yes — just not curative surgery. Patients who are not candidates for curative resection may still have palliative surgical procedures such as VATS partial pleurectomy, indwelling pleural catheters, or partial decortication to control fluid, relieve breathlessness, and improve quality of life.[1][6]

What is the difference between palliative and curative surgery for mesothelioma? Curative surgery aims to remove all visible tumor and extend survival; it carries significant risk and is reserved for carefully selected operable patients. Palliative surgery aims only to relieve symptoms — it accepts that tumor will remain and is judged by whether the patient feels better, not by cure.[2][4]

What is a partial pleurectomy for mesothelioma? A partial pleurectomy removes part of the tumor-bearing pleura — the lining around the lung — often through minimally invasive VATS access. When combined with decortication, it also peels the tumor rind off a lung that has become trapped, helping the lung re-expand and easing breathlessness.[6][11]

What is the University of Chicago partial pleurectomy trial, and who qualifies? NCT07126509 is a pilot trial testing limited partial pleurectomy in patients with unresectable or borderline-resectable epithelioid pleural mesothelioma. Qualifying patients must have epithelioid histology, have completed at least six weeks of systemic induction therapy without progression, and have an ECOG performance status of 0 to 1.[7]

What is the LCSS-Meso, and why does it matter? The LCSS-Meso is a validated questionnaire that measures mesothelioma symptoms — pain, breathlessness, fatigue, appetite loss, and impact on activity. It was validated in 495 unresectable patients and is the primary measure of whether palliative treatments, including surgery, actually reduce a patient's symptom burden.[14][12]

Can I receive immunotherapy and have palliative surgery? Yes — they are used together. Systemic therapy such as nivolumab plus ipilimumab is the backbone of treatment for unresectable disease, and palliative surgery is layered around it. In the University of Chicago trial, patients complete at least six weeks of induction therapy before surgery and resume systemic treatment afterward.[5][7]

Does being inoperable affect my right to compensation? No. Compensation depends on asbestos exposure and diagnosis, not on whether the tumor can be surgically removed. Trust fund claims, litigation, and VA benefits may all be available, and the statute of limitations makes filing promptly important.[3]

Quick Statistics

  • 18.1 vs 14.1 months — median overall survival with nivolumab plus ipilimumab versus chemotherapy in unresectable mesothelioma (CheckMate 743).[5]
  • 51 patients — the earliest formal palliative surgical debulking series, in which epithelioid histology predicted symptom control and survival.[11]
  • 495 patients — the validation cohort for the LCSS-Meso symptom instrument in unresectable disease.[14]
  • 30 patients — target enrollment for the University of Chicago partial pleurectomy pilot trial (NCT07126509).[7]
  • Epithelioid only — the histology requirement shared by the Martin-Ucar series and the active UChicago trial.[11][7]
  • No survival benefit — adding extended pleurectomy/decortication to chemotherapy in operable patients (MARS 2).[4]
  • Fewer hospital days — indwelling pleural catheters versus talc pleurodesis for malignant effusion (AMPLE trial).[8]
  • Multidisciplinary review — the Society of Thoracic Surgeons 2026 consensus standard for all mesothelioma surgical decisions.[3]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Kindler HL, Ismaila N, Armato SG, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-1373. PMID: 29346042. https://pubmed.ncbi.nlm.nih.gov/29346042/
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Bueno R, Opitz I. Surgery in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(11):1638-1654. PMID: 30121394. https://pubmed.ncbi.nlm.nih.gov/30121394/
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 Velotta JB, Roden AC, Rice J, et al. The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma. Ann Thorac Surg. 2026. PMID: 42019659. https://pubmed.ncbi.nlm.nih.gov/42019659/
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457-466. PMID: 38740044. https://pubmed.ncbi.nlm.nih.gov/38740044/
  5. ↑ 5.0 5.1 5.2 5.3 5.4 Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID: 33485464. https://pubmed.ncbi.nlm.nih.gov/33485464/
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118-1127. PMID: 24942631. https://pubmed.ncbi.nlm.nih.gov/24942631/
  7. ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 A Pilot Study of Partial Pleurectomy in Borderline and Unresectable Pleural Mesothelioma. University of Chicago Medicine Comprehensive Cancer Center. ClinicalTrials.gov identifier NCT07126509. https://clinicaltrials.gov/study/NCT07126509
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Thomas R, Fysh ETH, Smith NA, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017;318(19):1903-1912. PMID: 29164255. https://pubmed.ncbi.nlm.nih.gov/29164255/
  9. ↑ 9.0 9.1 9.2 9.3 Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383-2389. PMID: 22610520. https://pubmed.ncbi.nlm.nih.gov/22610520/
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019;55(1):116-132. PMID: 30060030. https://pubmed.ncbi.nlm.nih.gov/30060030/
  11. ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma: predictors of survival and symptom control. Eur J Cardiothorac Surg. 2001;20(6):1117-1121. PMID: 11717014. https://pubmed.ncbi.nlm.nih.gov/11717014/
  12. ↑ 12.0 12.1 12.2 12.3 Scherpereel A, Antonia S, Bautista Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022;167:8-16. PMID: 35367910. https://pubmed.ncbi.nlm.nih.gov/35367910/
  13. ↑ 13.0 13.1 Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. PMID: 32451346. https://pubmed.ncbi.nlm.nih.gov/32451346/
  14. ↑ 14.0 14.1 14.2 14.3 14.4 Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer. 2004;101(3):587-595. PMID: 15274072. https://pubmed.ncbi.nlm.nih.gov/15274072/
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Surgery_for_Unresectable_Pleural_Mesothelioma&oldid=3740"